Genexine Inc (095700) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.011x

Based on the latest financial reports, Genexine Inc (095700) has a cash flow conversion efficiency ratio of -0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.97 Billion ≈ $-2.02 Million USD) by net assets (₩260.01 Billion ≈ $176.21 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Genexine Inc - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Genexine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 095700 liabilities breakdown for a breakdown of total debt and financial obligations.

Genexine Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genexine Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Waton Financial Limited Ordinary Shares NASDAQ:WTF	0.105x
Astec LifeSciences Limited NSE:ASTEC	-0.020x
Seronics Co. Ltd KQ:042600	-0.029x
Sea Sonic Electronics Co Ltd TWO:6203	0.075x
STLLR Gold Inc. TO:STLR	-0.045x
Premia S.A. AT:PREMIA	0.007x
Ferro S.A. WAR:FRO	0.023x
Banque nationale de Belgique Société anonyme BR:BNB	N/A

Annual Cash Flow Conversion Efficiency for Genexine Inc (2009–2024)

The table below shows the annual cash flow conversion efficiency of Genexine Inc from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see Genexine Inc stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩261.68 Billion ≈ $177.34 Million	₩-1.65 Billion ≈ $-1.12 Million	-0.006x	+95.09%
2023-12-31	₩296.90 Billion ≈ $201.21 Million	₩-38.05 Billion ≈ $-25.79 Million	-0.128x	+11.07%
2022-12-31	₩276.15 Billion ≈ $187.15 Million	₩-39.80 Billion ≈ $-26.97 Million	-0.144x	-485.45%
2021-12-31	₩517.74 Billion ≈ $350.87 Million	₩-12.75 Billion ≈ $-8.64 Million	-0.025x	+41.89%
2020-12-31	₩535.60 Billion ≈ $362.97 Million	₩-22.69 Billion ≈ $-15.38 Million	-0.042x	+69.74%
2019-12-31	₩296.91 Billion ≈ $201.21 Million	₩-41.57 Billion ≈ $-28.17 Million	-0.140x	-123.77%
2018-12-31	₩320.51 Billion ≈ $217.20 Million	₩-20.05 Billion ≈ $-13.59 Million	-0.063x	+72.70%
2017-12-31	₩113.91 Billion ≈ $77.19 Million	₩-26.10 Billion ≈ $-17.69 Million	-0.229x	-176.72%
2016-12-31	₩170.24 Billion ≈ $115.37 Million	₩-14.10 Billion ≈ $-9.55 Million	-0.083x	-534.09%
2015-12-31	₩125.77 Billion ≈ $85.23 Million	₩-1.64 Billion ≈ $-1.11 Million	-0.013x	-135.88%
2012-12-31	₩45.83 Billion ≈ $31.06 Million	₩1.67 Billion ≈ $1.13 Million	0.036x	+125.17%
2011-12-31	₩24.04 Billion ≈ $16.29 Million	₩-3.48 Billion ≈ $-2.36 Million	-0.145x	+17.18%
2010-12-31	₩26.43 Billion ≈ $17.91 Million	₩-4.62 Billion ≈ $-3.13 Million	-0.175x	-19184.88%
2009-12-31	₩38.50 Billion ≈ $26.09 Million	₩35.23 Million ≈ $23.87K	0.001x	--

About Genexine Inc

KQ:095700 Korea Biotechnology

Market Cap

$167.36 Million

₩246.95 Billion KRW

Market Cap Rank

#17197 Global

#780 in Korea

Share Price

₩5430.00

Change (1 day)

-3.04%

52-Week Range

₩4280.00 - ₩7100.00

All Time High

₩131402.78